Share Name Share Symbol Market Type Share ISIN Share Description
N4 Pharma LSE:N4P London Ordinary Share GB00BYW8QM32 ORD 0.4P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.30p -16.46% 6.60p 5,845,798 16:12:39
Bid Price Offer Price High Price Low Price Open Price
6.30p 6.90p 9.15p 5.95p 8.10p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.93 -1.26 6.0

N4 Pharma (N4P) Latest News

More N4 Pharma News
N4 Pharma Takeover Rumours

N4 Pharma (N4P) Share Charts

1 Year N4 Pharma Chart

1 Year N4 Pharma Chart

1 Month N4 Pharma Chart

1 Month N4 Pharma Chart

Intraday N4 Pharma Chart

Intraday N4 Pharma Chart

N4 Pharma (N4P) Discussions and Chat

N4 Pharma Forums and Chat

Date Time Title Posts
25/9/201822:45N4 Pharma1,044
03/9/201815:34N4 Pharma - Making good drugs better.3,884

Add a New Thread

N4 Pharma (N4P) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-09-25 15:25:176.447,670493.95O
2018-09-25 15:24:286.6850,0003,339.95O
2018-09-25 15:12:046.543,670240.02O
2018-09-25 15:09:316.5713,563891.09O
2018-09-25 15:07:556.2032,1621,994.04O
View all N4 Pharma trades in real-time

N4 Pharma (N4P) Top Chat Posts

DateSubject
25/9/2018
09:20
N4 Pharma Daily Update: N4 Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker N4P. The last closing price for N4 Pharma was 7.90p.
N4 Pharma has a 4 week average price of 3.35p and a 12 week average price of 3.35p.
The 1 year high share price is 35.50p while the 1 year low share price is currently 3.35p.
There are currently 90,962,537 shares in issue and the average daily traded volume is 2,666,770 shares. The market capitalisation of N4 Pharma is £6,003,527.44.
07/9/2018
16:45
artyth2: OK, so Nigel isn't allowed to give us any "insider information" We are not asking for any. But, where is he hiding? Why no statements.?......"everything going to plan or not", whatever. I've basically written Sildenafil off, so any comeback is a bonus, but Nuvec, surely we deserve some loose statements as to how its fairing, without breaching any protocol. He was very quick to allow information out to smash the share price but seems loath to help get the share price back on its feet. Second hand info, spoon fed from Mr Hugh Wilson, aka David Farrier and Aim Chaos, aka Myles Mcnulty isn't good enough.
10/8/2018
13:19
jimbobaroony: Hugh, back in Feb when you were very bullish over N4P you accused me of deramping and posting "negative dribble". See below; "hughwilson7 Feb '18 - 20:12 - 1835 of 3883 As I said before, the Sildenafil is a reformulation of a proven drug to make it better. There is no basis for thinking N4's Viagra will be anything but successful. hughwilson7 Feb '18 - 21:53 - 1851 of 3883 The company itself is very bullish on its prospects. The company is ahead of its own timescales. It is already doing deals with the biggest pharmas in the world while being recognised snd funded by the British government. There are no negatives that I can see here and yet you spout nothing else but unsuported negative dribble. Don't pretend to be anything else (but a deramper)." This was becase I dared post the following suggesting that either could hammer the share price. "jimbobaroony 7 Feb '18 - 20:59 - 1843 of 3883 Edit For some yin to all your yang. Another catalyst (to drive share price).... - Delays / problems with their products - No deal announcements Pretty sure this is unlikely but its a possibility." I don't know how you can have the audacity to call us stupid!!! I am not in any way gloating at what has transpired (i am underwater here), however, it was always a possibility. Either you were too blind to see it, or didn't care as you had another agenda. Its one or the other!
03/8/2018
14:22
dplewis1: Haha ..glad I never read those but as ih_ jokingly points out this is a new (bottom tier) broker that also has connections to a substantial shareholder..the rose tinted specs are well and truly on. Granted, it will delve into each area of the business and seem professional but there will also be a lot of fluff about the addressable market size of sildenafil, the potential of the vaccines business etc. There will probably be some finger in the air share price prediction that will get people salivating. But it will not be widely digested and if there's a bump to the share price it could well suffer from 'post recommendation drift' in the weeks after.
14/7/2018
14:36
hughwilson: If my memory serves me correctly, that poster was at the time, bragging that the warrants were almost exhausted. The reality was that there was still over 15 million or way over half the warrants left. At the time the continuing issue of warrants was suppressing the share price, so a poster suggesting that the warrants were at an end is at best deception based on them not knowing what they were talking about OR if they did then an outright lie. Any person who states something as fact to a sensitive market should have done their sums first. The intention was to give the impression that that which was suppressing the share price was at an end which at the time was most certainly not. Very easy to say when you get caught out that you made a mistake but we can all add up and if that poster was unsure of how many warrants were left then he should not have posted in such a certain manner that they were ended.
16/6/2018
12:03
parob: Due to the recent rise and huge potential that N4 has, there's a lot of NEW interest in this stock and imo momentum alone could drive the price to new highs soon. Here are some POTENTIAL share price catalysts:- Further collaborations on Nuvec.- Nuvec licensing deal with MedImmune/AZ.- Commercial tie up for duloxetine reformulation.- Positive human trial results for Sildenafil - announcement due in Aug.- Broker upgrade to share price target.- Being tipped in the media/tipster websites.- Further holdings RNS/Institutional buying.- News on other patents.- News on other drugs being reformulated.- News on further grants.- Media coverage of any news listed above.
16/6/2018
11:12
hughwilson: Ch1rp, If N4 achieves its aims then the share price will be multiples of the share price today. The AimChaos report gave N4 a fair valuation of 95p at present. In that report he stresses throughout that his valuation is cautious and yet the potential is huge. That is why we have a potential £400m company valued at £25m.
13/6/2018
13:25
hughwilson: Today marks the 8 week mark. Within the next two weeks the results of the Sildenafil trials will be out, not for me or Jo public but for someone in the know so the news will be in the share price long before they are announced. We have already seen steady large buys for the last few weeks trying to build a share without attracting attention but if you see the share price really taking off over the next two weeks then you will know that you will be looking at good trial results.
03/2/2018
08:53
nick2412: Hugh, I guess the wording translates as MedImmune / AZ have the right to discuss and seek exclusivity whilst N4P retain the right to name their price. I think it would require a very large initial milestone payment for an exclusive license, or, alternatively, necessitate buying Nuvac outright for a sum that equates in the N4P share price to pounds rather than pence for AZ (or any other company for that matter) to achieve exclusivity. The studiy highlighting the differences between Nuvac and current / other DNA /RNA drug delivery methods should be published this quarter and perhaps before the Japan visit. Existing findings suggest that Nuvac will be in demand so the potential is a)a lucrative exclusive deal with AZ b) multiple licensing deals with different partners c) a bidding war to buy Nuvac outright. Early days but it's looking interesting to say the least.
03/7/2017
18:23
bdog51: I'm with you on that Flash. When the direction of travel reverses, the N4P share price can really motor. Bargain price down at these low levels right now. Just takes a bit of news flow to change the tide.
18/5/2017
12:50
someuwin: CEO owns 17% of the equity here. This is almost entirely from his own purchases on the market when this was ONZ (see repeated Holdings RNSs last year). Furthermore his consideration shares resulting from the new N4P listing are deferred until the N4P share price has been over 15p for 10 consecutive days. ...I don't think it will be too long before that situation occurs.
N4 Pharma share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180926 05:04:19